Category: Clinical Trials

Hydroxychloroquine Blood Levels in Primary Sjögren Syndrome Patients

https://clinicaltrials.gov/ct2/show/NCT04546542?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=08%2F31%2F2020&lupd_d=14&sort=nwst STUDY TITLE: Hydroxychloroquine Blood Levels in Primary Sjögren Syndrome Patients DESCRIPTION: Condition:   Sjogren’s SyndromeIntervention:   Other: Parallel AssignmentSponsor:   University of Sao Paulo General HospitalNot yet recruiting CLINICALTRIALS.GOV IDENTIFIER: NCT04546542 FIRST POSTED: Mon, 14 Sep 2020 12:00:00 EDT LAST UPDATE POSTED: 09/14/20 07:10AM STUDY LINK / URL: https://clinicaltrials.gov/ct2/show/NCT04546542?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=08%2F31%2F2020&lupd_d=14&sort=nwst

TrueTear in Sjogren’s Disease Patients

https://clinicaltrials.gov/ct2/show/NCT03719885?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=08%2F11%2F2020&lupd_d=14&sort=nwst STUDY TITLE: TrueTear in Sjogren’s Disease Patients DESCRIPTION: Conditions:   Dry Eye Syndromes;   Sjogren’s SyndromeIntervention:   Device: TrueTear Intranasal Tear NeurostimulatorSponsors:   University of Pennsylvania;   AllerganCompleted CLINICALTRIALS.GOV IDENTIFIER: NCT03719885 FIRST POSTED: Thu, 25 Oct 2018 12:00:00 EDT LAST UPDATE POSTED: 08/25/20 07:09AM STUDY LINK / URL: https://clinicaltrials.gov/ct2/show/NCT03719885?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=08%2F11%2F2020&lupd_d=14&sort=nwst

Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjögren’s Syndrome

https://clinicaltrials.gov/ct2/show/NCT03905525?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=10%2F14%2F2019&lupd_d=14&sort=nwst STUDY TITLE: Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjögren’s Syndrome DESCRIPTION: Condition:   Sjögren SyndromeInterventions:   Drug: CFZ533;   Other: PlaceboSponsor:   Novartis PharmaceuticalsRecruiting CLINICALTRIALS.GOV IDENTIFIER: NCT03905525 FIRST POSTED: Fri, 05 Apr 2019 12:00:00 EDT LAST UPDATE POSTED: 10/28/19 11:40AM STUDY LINK / URL: https://clinicaltrials.gov/ct2/show/NCT03905525?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=10%2F14%2F2019&lupd_d=14&sort=nwst

Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren’s Syndrome

https://clinicaltrials.gov/ct2/show/NCT04496960?type=Intr https://clinicaltrials.gov/ct2/show/NCT04496960?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=07%2F21%2F2020&lupd_d=14&sort=nwst STUDY TITLE: Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren’s Syndrome Phase Ib-IIa Placebo-Controlled Clinical Trial and Associated Mechanistic Studies DESCRIPTION: Condition:   Sjogren’s SyndromeInterventions:   Drug: tofacitinib;   Other: PlaceboSponsor:   National Institute of Dental and Craniofacial Research (NIDCR)Not yet recruiting CLINICALTRIALS.GOV IDENTIFIER: NCT04496960 FIRST POSTED: Tue, 04 Aug 2020 12:00:00 EDT […]

Involvement of Immune Cells Derived From the Intestine in Sjogren’s Syndrome

https://clinicaltrials.gov/ct2/show/NCT03841318?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=03%2F09%2F2020&lupd_d=14&sort=nwst STUDY TITLE: Involvement of Immune Cells Derived From the Intestine in Sjogren’s Syndrome DESCRIPTION: Condition:   Sjogren’s SyndromeInterventions:   Biological: blood sample;   Biological: biopsy of the labial salivary glandSponsor:   University Hospital, BordeauxNot yet recruiting CLINICALTRIALS.GOV IDENTIFIER: NCT03841318 FIRST POSTED: Fri, 15 Feb 2019 12:00:00 EST LAST UPDATE POSTED: 03/23/20 12:38PM STUDY LINK / URL: https://clinicaltrials.gov/ct2/show/NCT03841318?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=03%2F09%2F2020&lupd_d=14&sort=nwst

Intravenous Immunoglobulins for the Treatment of Primary Sjögren’s Syndrome Associated Painful Sensory Neuropathies

https://clinicaltrials.gov/ct2/show/NCT03700138?type=Intr https://clinicaltrials.gov/ct2/show/NCT03700138?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=07%2F13%2F2020&lupd_d=14&sort=nwst STUDY TITLE: Intravenous Immunoglobulins for the Treatment of Primary Sjögren’s Syndrome Associated Painful Sensory Neuropathies DESCRIPTION: Condition:   Primary Sjögren’s Syndrome Painful Sensory NeuropathiesInterventions:   Drug: Privigen® 100mg/ml at the dose of 2g/kg of body weight;   Drug: NaCl 0,9%Sponsor:   University Hospital, Strasbourg, FranceRecruiting CLINICALTRIALS.GOV IDENTIFIER: NCT03700138 FIRST POSTED: Tue, 09 Oct 2018 12:00:00 EDT LAST UPDATE […]

Fecal Microbial Transplant (FMT) for Sjogren’s Syndrome [Completed]

https://www.clinicaltrials.gov/ct2/show/NCT03926286?type=Intr&cond=Sjogren%27s+Syndrome&sort=nwst&draw=2&rank=9 Fecal Microbial Transplant (FMT) for Sjogrens Syndrome Study Description Go to sections Brief Summary: This is an open label study to evaluate the effect of Fecal Microbiota Transplantation (FMT) on the gut microbiome and Systemic parameters. Condition or disease Intervention/treatment Phase Sjogren’s Syndrome Drug: FMP-30 Phase 1 Study Design Go to sections Study Type […]

Safety and Efficacy of VAY736 in Patients With Primary Sjogren’s Syndrome (pSS)

https://www.clinicaltrials.gov/ct2/show/NCT02962895 Safety and Efficacy of VAY736 in Patients With Primary Sjogren’s Syndrome (pSS) Brief Summary: This study will determine the dose-response relationship of VAY736 for key efficacy and safety parameters Condition or disease Intervention/treatment Phase Primary Sjogren Syndrome Biological: VAY736 Other: Placebo Phase 2 Study Design Go to sections Study Type : Interventional (Clinical Trial) […]

Rebamipide for the Treatment of Xerostomia (Dry Mouth) in Sjögren Syndrome

https://clinicaltrials.gov/ct2/show/NCT01759108?type=Intr https://clinicaltrials.gov/ct2/show/NCT01759108?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=03%2F17%2F2020&lupd_d=14&sort=nwst STUDY TITLE: Rebamipide AND Sjögren Syndrome DESCRIPTION: Condition:   Improving Symptoms of Dry Mouth in Sjőgren’s SyndromeIntervention:   Drug: RebamipideSponsor:   University of AlexandriaRecruiting CLINICALTRIALS.GOV IDENTIFIER: NCT01759108 FIRST POSTED: Wed, 02 Jan 2013 12:00:00 EST LAST UPDATE POSTED: 03/31/20 09:29AM STUDY LINK / URL: https://clinicaltrials.gov/ct2/show/NCT01759108?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=03%2F17%2F2020&lupd_d=14&sort=nwst

Pilot Trial of Ustekinumab for Primary Sjögren’s Syndrome

https://clinicaltrials.gov/ct2/show/NCT04093531?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=10%2F08%2F2019&lupd_d=14&sort=nwst STUDY TITLE: Pilot Trial of Ustekinumab for Primary Sjögren’s Syndrome DESCRIPTION: Condition:   Primary Sjögren SyndromeIntervention:   Drug: UstekinumabSponsor:   University of RochesterNot yet recruiting CLINICALTRIALS.GOV IDENTIFIER: NCT04093531 FIRST POSTED: Wed, 18 Sep 2019 12:00:00 EDT LAST UPDATE POSTED: 10/22/19 07:00AM STUDY LINK / URL: https://clinicaltrials.gov/ct2/show/NCT04093531?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=10%2F08%2F2019&lupd_d=14&sort=nwst

A Clinical Trial to Evaluate the Safety and Efficacy of Traditional Chinese Medicine in Sjögren’s Syndrome [Completed]

https://www.clinicaltrials.gov/ct2/show/NCT04111341?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=09%2F17%2F2019&lupd_d=14&sort=nwst STUDY TITLE: A Clinical Trial to Evaluate the Safety and Efficacy of Traditional Chinese Medicine in Sjögren’s Syndrome. DESCRIPTION: Condition:   Sjögren’s SyndromeInterventions:   Drug: TCM (Gan-Lu-Yin)GLY;   Drug: PLACEBOSponsor:   Chung Shan Medical UniversityCompleted CLINICALTRIALS.GOV IDENTIFIER: NCT04111341 FIRST POSTED: Tue, 01 Oct 2019 12:00:00 EDT LAST UPDATE POSTED: 10/01/19 06:22PM STUDY LINK / URL: https://www.clinicaltrials.gov/ct2/show/NCT04111341?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=09%2F17%2F2019&lupd_d=14&sort=nwst

An Open-Label Phase 2 Study of INCB050465 in Participants With Primary Sjögren’s Syndrome

https://www.clinicaltrials.gov/ct2/show/NCT03627065 A Study of INCB050465 in Primary Sjögren’s Syndrome Brief Summary: The purpose of this study is to assess the impact of parsaclisib on the signs and symptoms of Sjögren’s syndrome (SS). Condition or disease Intervention/treatment Phase Primary Sjögren’s Syndrome Drug: Parsaclisib Phase 2 Study Design Go to sections Study Type : Interventional Estimated Enrollment […]